Amgen Inc. launched two final-stage studies of its monthly obesity treatment, a closely watched drug that would compete with blockbuster weight-loss medicines from Eli Lilly & Co. and Novo Nordisk A/S.
The two trials will test Amgen’s injectable drug, MariTide, in about 4,500 patients total, Amgen top scientist Jay Bradner said an investor conference Wednesday. One study will enroll patients diagnosed with obesity, and the other will recruit people with type 2 diabetes in addition.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.